AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 18588355 — intervention group
Group type: EXPERIMENTAL
Intervention: Atorvastatin 10 mg once daily
Number of subjects: 72
Study 18588355 — intervention group
Group type: EXPERIMENTAL
Intervention: NCB-02 (curcumin 150 mg twice daily)
Number of subjects: 72
Study 18588355 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 72
Study 16630994 — intervention group
Group type: EXPERIMENTAL
Intervention: FENO plus EZE
Number of subjects: 576
Study 14622893 — intervention group
Group type: EXPERIMENTAL
Intervention: Home-based intervention consisting of 10 weekly lessons focusing on child health and home safety.
Number of subjects: 63
Study 14622893 — intervention group
Group type: EXPERIMENTAL
Intervention: Home-based intervention
Number of subjects: 63
Study 10773185 — intervention group
Group type: EXPERIMENTAL
Intervention: Active treatment
Number of subjects: 0
Study 10773185 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 8846863 — intervention group
Group type: EXPERIMENTAL
Intervention: Tamoxifen (20 mg twice daily)
Number of subjects: 143
Study 8846863 — intervention group
Group type: COMPARATOR
Intervention: Radiotherapy (40 Gy)
Number of subjects: 143
Study 8846863 — intervention group
Group type: EXPERIMENTAL
Intervention: Tamoxifen (20 mg twice daily) after crossover
Number of subjects: 143
Study 8846863 — intervention group
Group type: COMPARATOR
Intervention: Radiotherapy (40 Gy) after crossover
Number of subjects: 143
Study 1444318 — intervention group
Group type: EXPERIMENTAL
Intervention: MAB-T88 (1 mg/kg)
Number of subjects: 9
Study 1444318 — intervention group
Group type: EXPERIMENTAL
Intervention: MAB-T88 (4 mg/kg)
Number of subjects: 9
Study 1444318 — intervention group
Group type: EXPERIMENTAL
Intervention: MAB-T88 (8 mg/kg)
Number of subjects: 9
Study 4036787 — intervention group
Group type: EXPERIMENTAL
Intervention: iopamidol
Number of subjects: 42
Study 4036787 — intervention group
Group type: EXPERIMENTAL
Intervention: urografin
Number of subjects: 42
Study 30919154 — intervention group
Group type: EXPERIMENTAL
Intervention: Structured exercise program of aerobic and active resistance exercises for 11 weeks
Number of subjects: 148
Study 30919154 — intervention group
Group type: COMPARATOR
Intervention: Standard physical activity recommendations
Number of subjects: 148
Study 29901441 — intervention group
Group type: EXPERIMENTAL
Intervention: Firehawk (bioabsorbable polymer sirolimus‐eluting stent)
Number of subjects: 1656
Study 29901441 — intervention group
Group type: COMPARATOR
Intervention: XIENCE (durable polymer drug‐eluting stent)
Number of subjects: 1656
Study 29901441 — intervention group
Group type: EXPERIMENTAL
Intervention: Firehawk
Number of subjects: 1656
Study 29901441 — intervention group
Group type: COMPARATOR
Intervention: XIENCE
Number of subjects: 1656
Study 27082108 — intervention group
Group type: EXPERIMENTAL
Intervention: Tamsulosin 0.4 mg daily for a maximum of 12 weeks
Number of subjects: 249
Study 27082108 — intervention group
Group type: COMPARATOR
Intervention: Traditional analgesia alone (Control Group)
Number of subjects: 249
Study 27082108 — intervention group
Group type: EXPERIMENTAL
Intervention: Tamsulosin 0.4 mg daily
Number of subjects: 249
Study 24158940 — intervention group
Group type: EXPERIMENTAL
Intervention: DA-6034 10, 20, 50, 100 or 200 mg single dose
Number of subjects: 67
Study 24158940 — intervention group
Group type: EXPERIMENTAL
Intervention: DA-6034 40, 100 or 200 mg/day multiple doses for 7 days
Number of subjects: 67
Study 24158940 — intervention group
Group type: COMPARATOR
Intervention: Placebo (not specified dosage)
Number of subjects: 67
Study 23046749 — intervention group
Group type: EXPERIMENTAL
Intervention: Sativex®
Number of subjects: 666
Study 23046749 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 666
Study 20035530 — intervention group
Group type: EXPERIMENTAL
Intervention: Laparoscopic Roux‐en‐Y gastric bypass (LRYGB)
Number of subjects: 60
Study 20035530 — intervention group
Group type: EXPERIMENTAL
Intervention: Laparoscopic biliopancreatic diversion with duodenal switch (LDS)
Number of subjects: 60
Study 17564669 — intervention group
Group type: EXPERIMENTAL
Intervention: Mechanical vibration (60 Hz) for 30 min using ATL massage devices
Number of subjects: 0
Study 17564669 — intervention group
Group type: COMPARATOR
Intervention: Placebo (non-vibratory) devices
Number of subjects: 0
Study 16601828 — intervention group
Group type: EXPERIMENTAL
Intervention: 270 microg/kg rFVIIa
Number of subjects: 42
Study 16601828 — intervention group
Group type: EXPERIMENTAL
Intervention: 90 microg/kg rFVIIa (3 doses at 3-hour intervals)
Number of subjects: 42
Study 16601828 — intervention group
Group type: COMPARATOR
Intervention: Both regimens
Number of subjects: 42
Study 16601828 — intervention group
Group type: EXPERIMENTAL
Intervention: rFVIIa
Number of subjects: 42
Study 14585671 — intervention group
Group type: EXPERIMENTAL
Intervention: HA/Vi vaccine
Number of subjects: 116
Study 14585671 — intervention group
Group type: COMPARATOR
Intervention: Avaxim vaccine
Number of subjects: 116
Study 10881952 — intervention group
Group type: EXPERIMENTAL
Intervention: Laparoscopic cholecystectomy (LC)
Number of subjects: 49
Study 10881952 — intervention group
Group type: COMPARATOR
Intervention: Open cholecystectomy (OC)
Number of subjects: 49
Study 8624269 — intervention group
Group type: EXPERIMENTAL
Intervention: Pamidronate 120 mg infusion
Number of subjects: 20
Study 1294606 — intervention group
Group type: EXPERIMENTAL
Intervention: PHZ102 (Inpharzam SA, Cadempino, Switzerland) containing EGF
Number of subjects: 0
Study 1294606 — intervention group
Group type: COMPARATOR
Intervention: Placebo eyedrops
Number of subjects: 0
Study 6387529 — intervention group
Group type: EXPERIMENTAL
Intervention: Diazepam (10 mg single dose and 30 mg/day for 2 weeks)
Number of subjects: 0
Study 6387529 — intervention group
Group type: EXPERIMENTAL
Intervention: Propranolol (80 mg single dose and 240 mg/day for 2 weeks)
Number of subjects: 0
Study 6387529 — intervention group
Group type: COMPARATOR
Intervention: Control (not specified)
Number of subjects: 0
Study 30168266 — intervention group
Group type: EXPERIMENTAL
Intervention: Elective inguinal hernia repair (open or laparoscopic)
Number of subjects: 103
Study 30168266 — intervention group
Group type: COMPARATOR
Intervention: Control group (patients undergoing surgery for other diseases)
Number of subjects: 103
Study 26907090 — intervention group
Group type: EXPERIMENTAL
Intervention: Breast milk containing FUT2-dependent oligosaccharides
Number of subjects: 266
Study 26907090 — intervention group
Group type: COMPARATOR
Intervention: Control (placebo group)
Number of subjects: 266
Study 26273143 — intervention group
Group type: EXPERIMENTAL
Intervention: Captopril pretreatment for 3 days (Cap3d)
Number of subjects: 0
Study 26273143 — intervention group
Group type: EXPERIMENTAL
Intervention: Single dose captopril (Cap1hr) before surgery with Iso (Cap1hr+Iso)
Number of subjects: 0
Study 26273143 — intervention group
Group type: EXPERIMENTAL
Intervention: Captopril (Cap) 24 hours before MI/R in rabbits
Number of subjects: 0
Study 26273143 — intervention group
Group type: EXPERIMENTAL
Intervention: Iso (isoflurane) in rabbits
Number of subjects: 0
Study 26273143 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination of captopril and Iso (Iso+Cap) in rabbits
Number of subjects: 0
Study 26273143 — intervention group
Group type: COMPARATOR
Intervention: Untreated control (Control)
Number of subjects: 0
Study 26273143 — intervention group
Group type: COMPARATOR
Intervention: Sham operation (Sham)
Number of subjects: 0
Study 26273143 — intervention group
Group type: COMPARATOR
Intervention: MI/R (I/R)
Number of subjects: 0
Study 24151017 — intervention group
Group type: EXPERIMENTAL
Intervention: Sevelamer carbonate (starting dose 800 mg three times daily)
Number of subjects: 205
Study 24151017 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 205
Study 24151017 — intervention group
Group type: EXPERIMENTAL
Intervention: Sevelamer carbonate
Number of subjects: 205
Study 22552763 — intervention group
Group type: EXPERIMENTAL
Intervention: Dabigatran etexilate 220 mg once daily
Number of subjects: 8135
Study 22552763 — intervention group
Group type: EXPERIMENTAL
Intervention: Dabigatran etexilate 150 mg once daily
Number of subjects: 8135
Study 22552763 — intervention group
Group type: EXPERIMENTAL
Intervention: Enoxaparin
Number of subjects: 8135
Study 19939335 — intervention group
Group type: EXPERIMENTAL
Intervention: Antimicrobial silver dressings
Number of subjects: 304
Study 19939335 — intervention group
Group type: COMPARATOR
Intervention: Non-adherent control dressings
Number of subjects: 304
Study 17495474 — intervention group
Group type: EXPERIMENTAL
Intervention: Venlafaxine
Number of subjects: 31
Study 17495474 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 31
Study 15037936 — intervention group
Group type: EXPERIMENTAL
Intervention: Micronized purified flavonoid fraction with routine antibiotic and anti‐inflammatory treatment
Number of subjects: 50
Study 15037936 — intervention group
Group type: COMPARATOR
Intervention: Routine antibiotic and anti‐inflammatory treatment alone (control)
Number of subjects: 50
Study 11779396 — intervention group
Group type: COMPARATOR
Intervention: Cold-adapted, live, attenuated, trivalent, intranasal influenza vaccine (CAIV-T)
Number of subjects: 0
Study 9090267 — intervention group
Group type: EXPERIMENTAL
Intervention: Mental arithmetic task with threat of shock
Number of subjects: 40
Study 9090267 — intervention group
Group type: COMPARATOR
Intervention: Mental arithmetic task without threat of shock
Number of subjects: 40
Study 7942878 — intervention group
Group type: EXPERIMENTAL
Intervention: Patient-controlled analgesia (PCA) with morphine sulfate 1 mg or meperidine hydrochloride 10 mg, six-minute lockout period
Number of subjects: 36
Study 7942878 — intervention group
Group type: COMPARATOR
Intervention: Intramuscular (i.m.) analgesic therapy with meperidine hydrochloride 75-100 mg every three to four hours as needed
Number of subjects: 36
Study 3392233 — intervention group
Group type: EXPERIMENTAL
Intervention: Nilvadipine 2 mg
Number of subjects: 6
Study 3392233 — intervention group
Group type: EXPERIMENTAL
Intervention: Nilvadipine 4 mg
Number of subjects: 6
Study 3392233 — intervention group
Group type: EXPERIMENTAL
Intervention: Nilvadipine 6 mg
Number of subjects: 6
Study 3392233 — intervention group
Group type: EXPERIMENTAL
Intervention: Nilvadipine (all doses)
Number of subjects: 6
Study 31008870 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.05 μg/kg/min norepinephrine
Number of subjects: 40
Study 31008870 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.5 μg/kg/min phenylephrine
Number of subjects: 40
Study 31008870 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.04 IU/min vasopressin
Number of subjects: 40
Study 31008870 — intervention group
Group type: COMPARATOR
Intervention: saline (control)
Number of subjects: 40
Study 29248107 — intervention group
Group type: EXPERIMENTAL
Intervention: RPSA
Number of subjects: 311
Study 29248107 — intervention group
Group type: COMPARATOR
Intervention: EVLA-RTF
Number of subjects: 311
Study 26980809 — intervention group
Group type: EXPERIMENTAL
Intervention: Subcutaneous 300 µg GCSF before implantation
Number of subjects: 112
Study 26980809 — intervention group
Group type: COMPARATOR
Intervention: Control group (no GCSF)
Number of subjects: 112
Study 25536499 — intervention group
Group type: EXPERIMENTAL
Intervention: (S)-citalopram (10mg/d)
Number of subjects: 15
Study 25536499 — intervention group
Group type: EXPERIMENTAL
Intervention: (R)-citalopram (10mg/d)
Number of subjects: 15
Study 25536499 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 15
Study 23622910 — intervention group
Group type: EXPERIMENTAL
Intervention: Coroflex Please
Number of subjects: 945
Study 23622910 — intervention group
Group type: COMPARATOR
Intervention: Taxus Liberte
Number of subjects: 945
Study 20864549 — intervention group
Group type: EXPERIMENTAL
Intervention: Weight management program with seven training sessions over 2.5 months
Number of subjects: 81
Study 20864549 — intervention group
Group type: COMPARATOR
Intervention: Control group (no specific intervention mentioned)
Number of subjects: 81
Study 19112802 — intervention group
Group type: EXPERIMENTAL
Intervention: 2% mequinol (4‐hydroxyanisole, 4HA) and 0.01% tretinoin (Solagé) applied twice daily for 3 months
Number of subjects: 0
Study 19112802 — intervention group
Group type: COMPARATOR
Intervention: Ethyl alcohol vehicle (control)
Number of subjects: 0
Study 17267375 — intervention group
Group type: EXPERIMENTAL
Intervention: Structured Practice
Number of subjects: 14
Study 12560952 — intervention group
Group type: EXPERIMENTAL
Intervention: Intermittent hypoxia exposure (OI) for 22 years
Number of subjects: 2
Study 12560952 — intervention group
Group type: EXPERIMENTAL
Intervention: Intermittent hypoxia exposure (SI) for 6 months
Number of subjects: 2
Study 12560952 — intervention group
Group type: COMPARATOR
Intervention: Residents at altitude (RA)
Number of subjects: 2
Study 12560952 — intervention group
Group type: COMPARATOR
Intervention: Soldiers at sea level (SL)
Number of subjects: 2
Study 12560952 — intervention group
Group type: EXPERIMENTAL
Intervention: Intermittent hypoxia exposure (OI and SI)
Number of subjects: 2
Study 10689271 — intervention group
Group type: EXPERIMENTAL
Intervention: Home-based, transtelephonically monitored cardiac rehabilitation
Number of subjects: 133
Study 10689271 — intervention group
Group type: COMPARATOR
Intervention: Standard on-site rehabilitation
Number of subjects: 133
Study 9338902 — intervention group
Group type: EXPERIMENTAL
Intervention: 10 mg intravenous metoclopramide
Number of subjects: 32
Study 9338902 — intervention group
Group type: COMPARATOR
Intervention: Intravenous saline placebo
Number of subjects: 32
Study 8415169 — intervention group
Group type: EXPERIMENTAL
Intervention: Glass ionomer cement with daily application of sodium fluoride gel (pH 5.8)
Number of subjects: 36
Study 8415169 — intervention group
Group type: EXPERIMENTAL
Intervention: Glass ionomer cement without topical fluoride
Number of subjects: 36
Study 3535055 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral norfloxacin (400 mg every 12 hours)
Number of subjects: 68
Study 31967599 — intervention group
Group type: EXPERIMENTAL
Intervention: Quadriceps tendon (QT) autograft
Number of subjects: 28
Study 31967599 — intervention group
Group type: COMPARATOR
Intervention: Hamstring tendon (HT) autograft
Number of subjects: 28
Study 29367449 — intervention group
Group type: EXPERIMENTAL
Intervention: Zonisamide 50 mg once daily
Number of subjects: 158
Study 29367449 — intervention group
Group type: EXPERIMENTAL
Intervention: Zonisamide 25 mg once daily
Number of subjects: 158
Study 29367449 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 158
Study 28365440 — intervention group
Group type: EXPERIMENTAL
Intervention: Valproic acid (VPA)
Number of subjects: 66
Study 28365440 — intervention group
Group type: COMPARATOR
Intervention: Lamotrigine (LTG)
Number of subjects: 66
Study 25559913 — intervention group
Group type: EXPERIMENTAL
Intervention: Motivational interviewing intervention over 90 days
Number of subjects: 0
Study 25559913 — intervention group
Group type: COMPARATOR
Intervention: Care as usual (control group)
Number of subjects: 0
Study 23428884 — intervention group
Group type: EXPERIMENTAL
Intervention: Treadmill training for 5 weeks (3 sessions/week)
Number of subjects: 22
Study 23428884 — intervention group
Group type: COMPARATOR
Intervention: Overground walking training for 5 weeks (3 sessions/week)
Number of subjects: 22
Study 21561933 — intervention group
Group type: EXPERIMENTAL
Intervention: Neurofeedback (NF)
Number of subjects: 41
Study 21561933 — intervention group
Group type: EXPERIMENTAL
Intervention: Standard computer format (SCF)
Number of subjects: 41
Study 21561933 — intervention group
Group type: COMPARATOR
Intervention: Waitlist control group
Number of subjects: 41
Study 18505757 — intervention group
Group type: EXPERIMENTAL
Intervention: Contact with a befriender facilitator and offer of match with a trained lay volunteer befriender
Number of subjects: 236
Study 18505757 — intervention group
Group type: COMPARATOR
Intervention: No befriender facilitator contact (Control)
Number of subjects: 236
Study 17348239 — intervention group
Group type: EXPERIMENTAL
Intervention: Current wheeze
Number of subjects: 7549
Study 17348239 — intervention group
Group type: EXPERIMENTAL
Intervention: Past 12 months wheeze
Number of subjects: 7549
Study 17348239 — intervention group
Group type: EXPERIMENTAL
Intervention: Self-reported asthma
Number of subjects: 7549
Study 17348239 — intervention group
Group type: EXPERIMENTAL
Intervention: Current rhinitis
Number of subjects: 7549
Study 17348239 — intervention group
Group type: EXPERIMENTAL
Intervention: Rhinoconjunctivitis
Number of subjects: 7549
Study 17348239 — intervention group
Group type: EXPERIMENTAL
Intervention: Current chronic rash
Number of subjects: 7549
Study 17348239 — intervention group
Group type: EXPERIMENTAL
Intervention: Chronic rash with flexural distribution
Number of subjects: 7549
Study 17348239 — intervention group
Group type: EXPERIMENTAL
Intervention: Family history of allergy
Number of subjects: 7549
Study 17348239 — intervention group
Group type: EXPERIMENTAL
Intervention: Concurrent rhinoconjunctivitis
Number of subjects: 7549
Study 17348239 — intervention group
Group type: EXPERIMENTAL
Intervention: Concurrent chronic flexural rash
Number of subjects: 7549
Study 17348239 — intervention group
Group type: EXPERIMENTAL
Intervention: Previous respiratory infection
Number of subjects: 7549
Study 14674148 — intervention group
Group type: EXPERIMENTAL
Intervention: HRT + statin (Systen Sequi, Cilag + Zocor, MSD)
Number of subjects: 75
Study 14674148 — intervention group
Group type: EXPERIMENTAL
Intervention: HRT + statin (Systen Conti, Cilag + Zocor, MSD)
Number of subjects: 75
Study 14674148 — intervention group
Group type: EXPERIMENTAL
Intervention: statin only (Zocor, MSD)
Number of subjects: 75
Study 14674148 — intervention group
Group type: COMPARATOR
Intervention: HRT (Systen Sequi, Cilag)
Number of subjects: 75
Study 14674148 — intervention group
Group type: COMPARATOR
Intervention: HRT (Systen Conti, Cilag)
Number of subjects: 75
Study 11127128 — intervention group
Group type: EXPERIMENTAL
Intervention: Soft contact lens (Hydron Zero 6) wear
Number of subjects: 55
Study 11127128 — intervention group
Group type: EXPERIMENTAL
Intervention: Self‐prepared cotton thread test (SP‐CTT)
Number of subjects: 55
Study 11127128 — intervention group
Group type: EXPERIMENTAL
Intervention: NITBUT and PRT tests
Number of subjects: 55
Study 11127128 — intervention group
Group type: EXPERIMENTAL
Intervention: Wetting values (combinations of NITBUT and SP‐CTT or NITBUT and PRT)
Number of subjects: 55
Study 11127128 — intervention group
Group type: EXPERIMENTAL
Intervention: SP‐CTT
Number of subjects: 55
Study 8865706 — intervention group
Group type: EXPERIMENTAL
Intervention: 3 l. min(‐1) oxygen with face mask for the initial 3 hours
Number of subjects: 48
Study 8865706 — intervention group
Group type: COMPARATOR
Intervention: Room air
Number of subjects: 48
Study 8865706 — intervention group
Group type: EXPERIMENTAL
Intervention: 3 l. min(‐1) oxygen inhalation through the face mask
Number of subjects: 48
Study 1469341 — intervention group
Group type: EXPERIMENTAL
Intervention: Manipulation (high-velocity, low-amplitude thrust)
Number of subjects: 100
Study 1469341 — intervention group
Group type: COMPARATOR
Intervention: Mobilization (muscle energy technique)
Number of subjects: 100
Study 6435655 — intervention group
Group type: EXPERIMENTAL
Intervention: Ro 15‐1788 (5 mg i.v.)
Number of subjects: 6
Study 6435655 — intervention group
Group type: EXPERIMENTAL
Intervention: Ro 15‐3505
Number of subjects: 6
Study 6435655 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 6
Study 31259655 — intervention group
Group type: EXPERIMENTAL
Intervention: FPS 100/50 μg once daily (QD)
Number of subjects: 34
Study 31259655 — intervention group
Group type: EXPERIMENTAL
Intervention: FPS 100/50 μg twice daily (BID)
Number of subjects: 34
Study 31259655 — intervention group
Group type: EXPERIMENTAL
Intervention: FPS 250/50 μg BID
Number of subjects: 34
Study 31259655 — intervention group
Group type: EXPERIMENTAL
Intervention: FPS 500/50 μg BID
Number of subjects: 34
Study 31259655 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 34
Study 27905266 — intervention group
Group type: EXPERIMENTAL
Intervention: Breaks with stretching
Number of subjects: 30
Study 27905266 — intervention group
Group type: EXPERIMENTAL
Intervention: Breaks with dynamic movement
Number of subjects: 30
Study 27905266 — intervention group
Group type: EXPERIMENTAL
Intervention: Passive breaks
Number of subjects: 30
Study 26977121 — intervention group
Group type: EXPERIMENTAL
Intervention: Standardised Fermented Papaya Gel (SFPG) applied intragingivally (7 g) for 15 minutes daily for 10 days
Number of subjects: 84
Study 26977121 — intervention group
Group type: COMPARATOR
Intervention: Control group (traditional pharmacologic/surgical protocols)
Number of subjects: 84
Study 26977121 — intervention group
Group type: EXPERIMENTAL
Intervention: Standardised Fermented Papaya Gel (SFPG)
Number of subjects: 84
Study 24131045 — intervention group
Group type: EXPERIMENTAL
Intervention: In-home cognitive training program
Number of subjects: 68
Study 24131045 — intervention group
Group type: COMPARATOR
Intervention: Life story interview
Number of subjects: 68
Study 22939114 — intervention group
Group type: EXPERIMENTAL
Intervention: Standardized grading of OCT images by CATT readers (2 independent readers and a senior reader)
Number of subjects: 270
Study 22939114 — intervention group
Group type: EXPERIMENTAL
Intervention: Independent reading center team measurements of total thickness at the foveal center point
Number of subjects: 270
Study 21186968 — intervention group
Group type: EXPERIMENTAL
Intervention: Psychostimulants (amphetamine)
Number of subjects: 52
Study 21186968 — intervention group
Group type: COMPARATOR
Intervention: Psychotropic treatment history
Number of subjects: 52
Study 16936304 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral contraceptive pill (OCP) [ethinyl estradiol (E(2)) 30 microg + desogestrel 150 microg]
Number of subjects: 93
Study 16936304 — intervention group
Group type: EXPERIMENTAL
Intervention: Norethisterone 10 mg/day
Number of subjects: 93
Study 16936304 — intervention group
Group type: EXPERIMENTAL
Intervention: 17-betaE(2) 4 mg/day
Number of subjects: 93
Study 16936304 — intervention group
Group type: COMPARATOR
Intervention: No pre-treatment
Number of subjects: 93
Study 16392443 — intervention group
Group type: EXPERIMENTAL
Intervention: Ankle Stabilizing Orthosis (ASO)
Number of subjects: 15
Study 11865342 — intervention group
Group type: EXPERIMENTAL
Intervention: Ultrasonically activated coagulated shears (UACS)
Number of subjects: 40
Study 11865342 — intervention group
Group type: COMPARATOR
Intervention: Monopolar electrosurgery
Number of subjects: 40
Study 11255520 — intervention group
Group type: COMPARATOR
Intervention: Placebo for 14 days, followed by full‐dose (10 mg) ramipril until day 90
Number of subjects: 352
Study 11255520 — intervention group
Group type: EXPERIMENTAL
Intervention: Low‐dose (0.625 mg) ramipril for 90 days
Number of subjects: 352